Efficacy and safety of adalimumab in the treatment of Crohns disease in children / Eficacia y seguridad del adalimumab en el tratamiento de la enfermedad de Crohn infantil
Rev. esp. enferm. dig
; 105(10): 579-584, nov.-dic. 2013. tab, ilus
Article
in En
| IBECS
| ID: ibc-119285
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Objectives: to describe the efficacy and safety of adalimumab (ADA) in inducing clinical remission and reducing inflammation of intestinal mucosa in children with Crohns disease (CD). Methods: we carried out a descriptive, observational study with all patients diagnosed with CD and treated with ADA between January 2007 and March 2013. Disease activity was determined using the Pediatric Crohns Disease Activity Index (PCDAI), and the degree of mucosa inflammation by fecal calprotectin (FC). Results: sixteen patients were included. Mean age at diagnosis was 10.6 ± 2.5 years, with a mean age at start of ADA treatment of 12.4 ± 1.8 years, and a median of 1.4 years (IQR 0.5-3) duration from CD diagnosis to start of treatment. Twelve patients were naïve to anti-TNF-a. The PCDAI score at start of ADA treatment was significantly reduced at 12 weeks of follow-up (31.25 IQR 26.8-37.5 vs. 1.2 IQR 0.0-5.0; p = 0.001). Similarly, the FC level decreased at 12 weeks (749 μg/g IQR 514-898 vs. 126 μg/g IQR 67.7-239.2; p = 0.02). Surgery was performed in 4 patients. Adverse events were reported in 4 patients. One patient developed lymphoma at 4 years of ADA treatment in monotherapy. Conclusions: ADA has been shown to be effective in children with moderate-to-severe CD. Treatment benefits should be weighed against side effects. Multicenter longitudinal studies with longer follow- up periods are required to determine the true efficacy and safety of long-term ADA treatment (AU)
RESUMEN
No disponible
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Biological Therapy
/
Crohn Disease
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Child
/
Female
/
Humans
/
Male
Language:
En
Journal:
Rev. esp. enferm. dig
Year:
2013
Document type:
Article